Header

Specialist Preclinical Drug Discovery CRO

Ion channels
Cardiac safety
Neuroscience

Leaders in ion channel, cardiac safety and neuroscience screening

Metrion Biosciences home page

Our Mission

To deliver specialist advice and expertise, high quality preclinical data and outstanding customer service. To empower the success of our customers’ pharmaceutical research and development.
WHY CHOOSE METRION AS YOUR CRO
Lastest News
Upcoming Events
Expanding our high-throughput ion channel screening capacity

Expanding our high-throughput ion channel screening capabilities.

Supporting ion channel biologics discovery: Why functional electrophysiology is critical

Biologic modalities may offer opportunities to achieve levels of subtype selectivity that can be difficult to obtain using traditional small molecules, particularly across closely related ion channel family members. This may enable more precise modulation of disease-relevant targets while potentially reducing unwanted off-target activity.

View All News
Society for Neuroscience Annual Meeting 2026

14th - 18th November 2026

Washington, USA

Chris Mathes PhD, General Manager of North America, and Tony Rush, PhD, Director, Neuroscience & Commercial Operations, will attend the SfN annual meeting. Tony will be presenting the poster: A Validated hNav1.9 Screening Cascade for Pain Discovery

View All Events
  • I’ve worked with a lot of ion channel CROs around the world and I really liked working with Metrion.

    The data quality was high, and they provided spreadsheets in an organized and readable format. Not everyone does that!

    Biotech

    USA
  • I've been pleased with the efficiency of the Metrion team, especially with their scientific expertise/practical ion channel knowledge. It’s not every ephys CRO that can make intellectual contributions towards the assay design and troubleshooting, and I've definitely appreciated that.

    John Gilchrist, Principal Scientist, 
    Latigo Biotherapeutics Inc.

    USA
  • Aligos values the consistency and convenience of working with Metrion. The data is always correct and is in a format that imports directly into our systems, making it so quick and easy for our team to review the data across individual projects. Metrion are always on top of the regulations as they change – they were incredibly helpful in supporting us navigate the ICH changes a while ago.

    Dr Dinah Misner, VP, Aligos Therapeutics

    USA
  • A big thank you for all the work you have done together with us. We just achieved the important milestone of transitioning into lead optimisation. Without you this would not be possible.

    Pharma

    EU
  • As another happy customer, I can add that I recently got data from Metrion scientists for manual electrophysiology testing of compounds against a native cell current. The data look fantastic and reproduced the recombinant cell potency. I gave them no information about the compounds, and they noted that one was a state-dependent blocker, showed example traces, and reported IC50s for peak current inhibition and area under the trace. They are also very careful in how they solubilize, dilute and store the samples.

    Top pharma

    USA
  • At Aligos, we have used Metrion's services for hERG, Nav1.5, and Cav1.2 screening routinely. Additionally, we have conducted long-term incubation with cardiomyocytes and measured functional endpoints for selected compounds where appropriate.

    Dr Dinah Misner, VP, Aligos Therapeutics

    USA
  • We are very encouraged by the data and appreciate the detailed description of the analysis. These discussions are very useful to the team and highlight the complexities of these experiments in terms of execution and interpretation.

    Drug Discovery and Development Company

    USA
  • We recognize this type of study is very difficult and the cells we provided posed technical challenges. We also appreciate the timeliness of the study execution and the detailed report you provided.

    TOP 10 PHARMA

    GLOBAL
  • We appreciate the thoroughness, clearness of explanation and results, and the work done above and beyond to troubleshoot.

    BIOPHARMACEUTICAL COMPANY

    USA
  • I have no hesitation in recommending Metrion as a CRO for preclinical drug discovery. Everyone in the Metrion team has been a pleasure to work with – I couldn’t think of anything I would change or improve about the way they work.

    Dr Dinah Misner, VP, Aligos Therapeutics

    USA
  • Brilliant – both response time to my email and turnaround time for compounds!

    BIOTECH

    Germany
  • This data is excellent which gives me confidence for your assays. I look forward to working with you on more studies.

    large pharma

    USA
  • Really good data showing exactly what we would expect for a [target] inhibitor; we know how difficult these recordings are to perform.

    Large Pharmaceutical Company

    UK
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram